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Abstract 
Purpose: To investigate the anticancer activity of scopoletin against human prostate cancer. 
Methods: The anticancer activity of scopoletin was evaluated by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MMT) assay. Flow cytometry using propidium iodide and annexin V-FITC 
was employed to study apoptosis and cell cycle analysis. Hoechst 33258 staining was used to assess 
the effect of scopoletin on cell morphology and apoptotic body formation in human prostate carcinoma 
(LNCaP) cells via Florescence microscopy and finally Western blotting was used to evaluate the effect 
of scopoletin on cyclin D1 and cyclin B1 expressions. 
Results: Scopoletin induced a dose-dependent growth inhibition in LNCaP prostate cancer cells. It 
induced G2/M phase growth arrest and led to an increase in the sub-G0/G1 cell population after 
treatment with increasing doses compared to control cells, scopoletin treatment resulted in cell 
shrinkage along with membrane blebbing which are characteristic features of cell apoptosis. 
Approximately 15.45, 32.6 and 21.71 % of the cells underwent early apoptosis after treatment with 40, 
80 and 100 µM of scopoletin respectively. Cyclin D expression diminished in a concentration-dependent 
manner when LNCaP cells were treated with different concentrations of scopoletin. 
Conclusion: These results reveal that scopoletin may be used as a natural chemotherapeutic agent 
against prostate cancer. 
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Prostate cancer is the most frequently diagnosed 
malignancy in males and the second leading 
cause of cancer-related death in men after lung 
cancer in United States of America [1]. Despite a 
similar prevalence of latent prostate tumors 
around the globe, incidence rates for clinical 
prostate cancer in Western men are 30-50 times 
higher than those for Asian men and the reason 
for this difference is unclear. In the United States, 
prostate cancer accounts for 32 % of all cancer 
cases in men whereas in Shanghai (China), 
prostate cancer accounts for less than 1 % of all 
cancers in men.  
 
However, recent data suggest that prostate 
cancer rates are increasing [1]. In spite of 
substantial progress in prostate cancer 
treatment, the survival rate for advanced stages 
of this particular cancer has not considerably 
improved during the past decade [2,3]. 
Furthermore, standard treatment preferences for 
localized prostate cancer (surgical, radiation, and 
hormonal therapy) are accompanied with 
complications that often deteriorate patients’ 
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quality of life, such as urinary incontinence and 
sexual dysfunction. Therefore, prostate cancer 
patients seek complementary and alternative 
medicine (CAM) treatments in the hope of 
suppressing or slowing down disease 
progression to improve the general quality of life. 
Recent surveys demonstrated that approximately 
40 % of prostate cancer patients utilize various 
CAM modalities as a component of therapy [4-6]. 
 
Scopoletin (6-methoxy-7-hydroxycomarin) is a 
phenolic coumarin and an important member of 
the group of phytoalexins isolated from many 
plants, and also a prominent coumarin derivative 
occurring in various plants [7-10]. It has also 
been reported to be an active component in the 
plants such as Erycibe obtusifolia, Aster tataricus 
and Foeniculum vulgare. These plants have 
been used in traditional Chinese medicines for 
the treatment of various diseases with a long 
history. A variety of biological activities like anti-
inflammatory, anti- allergy and anti-angiogenesis 
have been reported for scopoletin [11-14]. The 
aim of the current research work was to evaluate 
the anticancer activity of scopoletin against 
prostate cancer cells in vitro by studying its effect 




Chemicals and reagents 
 
Scopoletin was purchased from Sigma Chemical 
Company (St Louis, MO, USA).Growth medium 
RPMI-1640 (Hangzhou Sijiqing Biological 
Products Co, Ltd, China), Minimum Essential 
Medium (MEM) (Invitrogen Corp, Carlsbad, CA, 
USA), Fetal Calf Serum (Gibco Corp, Carlsbad, 
CA, USA), trypsin, penicillin, MTT, streptomycin, 
DMSO and phosphate buffer saline (PBS) 
(Sigma) were used in this study. MTT kit was 
obtained from Roche (USA). Annexin V-FITC-
Propidium Iodide Apoptosis Detection Kit was 
purchased from Sigma (USA). All other 
chemicals and solvents used were of the highest 
purity grade. Cell culture plastic ware was 




Human prostate carcinoma (LNCaP) cells were 
procured from the Shanghai Institute of Cell 
Resource Center of Life Science (Shanghai, 
China). The cells were grown in a humidified 5 % 
CO2 atmosphere at 37 oC in an incubator, and 
cultured in RPMI-1640 medium supplemented 
with 10 % heat-inactivated newborn calf serum, 
100 IU/mL penicillin and 100 μg/mL 
streptomycin. 
Cell viability assay 
 
The in vitro cytotoxic effect of scopoletin toward 
human prostate cancer cells (LNCaP) was 
determined using 3-(4, 5-dimethylthiazol-2-yl)-2, 
5-diphenyltetrazolium bromide (MTT) assay. 
Cells (5 × 103 cells per well) were seeded onto a 
96-well plate for 24 h, treated with various 
concentrations (20, 40, 60, 80 and 100 µM) of 
Scopoletin, and incubated for an additional 2 
days at 37 oC. Thereafter, 10 μL of MTT at a 
concentration of 5 mg/mL was added to each 
well, and cells were incubated for an additional 
4–6 h. The supernatant was aspirated, and 100 
μL of DMSO was added to the wells to dissolve 
any precipitate present. The absorbance was 
measured in an ELISA reader (Thermo Molecular 
Devices Co, Union City, USA) at 570 nm. 
  
Cell inhibition ratio (C) was calculated as in Eq 1.  
 
C (%) = {(Ac At)/Ac}100 ……………………. (1) 
 
Cytotoxicity was expressed as the concentration 
of scopoletin inhibiting cell growth by 50 % (IC50). 
 
Cell cycle analysis by flow cytometry 
 
LNCaP cells (1 × 106) were seeded in 60-mm 
dishes and subjected to various concentrations 
(0, 40, 80, 100 μM) of scopoletin for 48 h. 
Floating and adherent cells were trypsinized and 
washed three times with PBS. Cells were 
incubated in 70 % ethanol at -20 °C overnight, 
treated with 20 µg/mL RNase A, and stained with 
5.0 µg/mL of propidium iodide. Finally the stained 
cells were analyzed and studied by Flow 
cytometry at wavelength of 488 nm (FACS 
Calibur instrument, BD Biosciences, San Jose, 
CA, USA) equipped with Cell Quest 3.3 software. 
 
Apoptosis detection using Hoechst 33258 
staining 
 
LNCaP cells were fixed with 4 % formaldehyde in 
phosphate buffered saline (PBS) for 30 min 
before staining with 10 μg/mL of Hoechst 33258 
at 37 oC for 20 min. The cells were treated with 
different concentrations (0, 40, 80, 100 μM) of 
scopoletin for 48 h. They were then washed once 
with PBS, and observed under a fluorescence 
microscope (Nikon). A minimum of 600 cells was 
counted, and each experiment was performed in 
triplicate. 
 
Detection of early and late apoptosis, and 
necrosis by annexin V binding assay 
 
Apoptosis was demonstrated by annexin V 
binding assay using flow cytometry. Briefly, 
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LNCaP cells were treated with different 
concentrations (0, 40, 80 and 100 μM) of 
scopoletin for 48 h. Subsequently, treated and 
untreated cells were harvested by trypsinization. 
Harvested cells were then incubated in annexin 
V-FITC (100ng/mL) and propidium iodide (40 
µg/mL), at room temperature for 30 min in dark, 
and analysed using a FACS Calibur flow 
cytometer (BD Bioscience). 
 
Western blot analysis 
 
To assess the dose-dependent effect of 
scopoletin, LNCaP cells were treated for 48 h 
with various concentrations of scopoletin, (20, 
40, 60 and 80 µM to determine the expression 
levels of cyclin D1 and cyclin B1). Cellular 
proteins were extracted using a cell lysis buffer 
containing 75 mM Tris-HCl (pH 7.6), 125 mM 
NaCl, 0.1 % sodium dodecyl sulfate (SDS), 1 % 
NP-40, and 1X proteinase inhibitor cocktail 
(Roche Applied Science, Indianapolis, IN) [11]. 
Twenty five micrograms of protein was 
fractionated by electrophoresis through a 20 % 
SDS polyacrylamide gel, and the proteins were 
transferred onto a nitrocellulose membrane. The 
membrane was further incubated with a 
secondary anti-rabbit antibody conjugated with 
horseradish peroxidase (Amersham, Arlington 
Heights, IL), and the specific protein was 
detected using a chemiluminescent method 
(Amersham) followed by autoradiography 
according to manufacturer’s instructions. This 
procedure was repeated for the detection of 
cyclin D1 and cyclin B1 proteins, using polyclonal 
rabbit IgG antibodies at a 1:200 dilution (Santa 




All statistical analyses were carried out with 
SPSS® software (version 19.0) based on one-
way analysis of variance (ANOVA) and Tukey 
test. Data are expressed as mean ± SEM, and p 




Anti-proliferative activity of scopoletin 
 
The effect of scopoletin treatment on the prostate 
cancer cell viability is shown in Fig 1. Scopoletin 
exhibited potent and dose-dependent cytotoxic 
activity against these cancer cells. The IC50 value 
of the extract was calculated to be 65.1 µM. As 
shown in Figure 1, 100 µg/mL extract exhibited a 
very strong anti-proliferative effect at which 
approximately only 7.91 % of the cells were 
found live and 92 %  dead. 
 
Effect of scopoletin on cell cycle phase 
distribution in human prostate cancer cells 
(LNCaP) 
 
The results showed that treatment with different 
concentrations of scopoletin for 48 h led to an 
increase in the population of cells in the sub-





Figure 1: Cancer growth inhibition shown by scopoletin against prostate cancer cells in vitro at various 
concentrations; *p < 0.05 vs. control group; **p < 0.01 vs. control group 
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The decline in the S phase population was 
attended by considerably increased G2/M phase 
population (p < 0.01) after 48 h treatment 
compared to the control, suggesting cell cycle 
arrest at the G2/M phase in scopoletin-treated 
cells. At 80 and 100 µM scopoletin, the cells had 
no increment in the G2/M population but 
increased in the sub-G1 population compared to 
the control, suggesting that cells were arrested at 
the G2/M phase followed by significant apoptotic 
cell death over time. 
 
Hoechst 33258 staining to detect apoptosis in 
LNCaP cancer cells  
 
Scopoletin treatment resulted in the appearance 
of cell shrinkage along with membrane blebbing 
which are characteristic features of cell apoptosis 
(Fig 3). 
 
Effect of scopoletin on early and late 
apoptosis, and necrosis in LNCaP cells 
 
The results of the flow cytometry study with 
Annexin V/FITC and PI showed that within 48 h 
of incubation, approximately 15.45, 32.6 and 
21.71 % of the cells underwent early apoptosis 
after treatment with 40, 80 and 100 µM of 
scopoletin respectively. Similarly, 6.0, 15.71 and 
54.1 % of the cells underwent late apoptosis after 
treatment with 40, 80 and 100 µM of scopoletin, 
respectively. Necrotic cell death also increased 
from 0.21 % (control, untreated cells) to 2.1, 6.31 
and 9.11 % after treatment with 40, 80 and 100 
µM of scopoletin, respectively as shown in Fig 4. 
 
Effect of scopoletin on cell cycle–regulating 
molecules (cyclin D1 and Cyclin B1) 
 
Cyclin D expression diminished in a 
concentration-dependent manner when LNCaP 
cells were treated with different concentrations 
(20, 40, 60 and 80 µM) of scopoletin (Fig. 5). 
Thus scopoletin inhibits the expression of cyclin 
D1 in human prostate cancer cells resulting in 
G2/M cell cycle arrest. The level of expression of 





Figure 2: Effect of scopoletin on cell cycle phase distribution in LNCaP cells. Scopoletin induces cell cycle arrest 
at G2/M phase in human prostate cancer (LNCaP) cells and increased G0/G1 (apoptotic) cell population. The cell 
cycle distribution was determined by propidium iodide staining and flow cytometry. LNCaP cells were treated with 
scopoletin at different concentrations (40, 80 and 100 µM, B, C and D respectively). Untreated cells (A) were 
included as controls. The DNA histogram shows the distribution and the percentage of cells in phases of the cell 
cycle. Results are the mean ± SD of 3 independent experiments; p < 0.01 compared to the control. Each DNA 
histogram represents one of the three independent experiments 
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Figure 3: Induction of apoptotic nuclear morphology of LNCaP cells treated with scopoletin. Nuclear morphology 
was analyzed by fluorescence microscopy upon staining with Hoechst 33258. LNCaP cells were cultured in the 
absence (A) or presence of 40 μM (B), 80 μM (C) and 100 μM (D) of scopoletin for 48 h, stained with Hoechst 





Figure 4: Induction of apoptosis by scopoletin and confirmation by Annexin V-FITC/PI dual staining. LNCaP cells 
were treated with 40 μM (B), 80 μM (C) and 100 μM (D) of scopoletin for 48 h and analysed using FACS Calibur 
flow cytometer as described in Experimental section. A, represents experiment control of untreated cells alone. 
Normal healthy, early apoptotic, late apoptotic and dead/necrotic cell populations are shown as percentage of 
total cells in the quadrants R3, R4, R2 and R1, respectively 
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Figure 5: Effect of Scopoletin on cyclin D1 and cyclin B1 protein expression. LNCaP and PC-3 cells were treated 
with various indicated concentrations of scopoletin for 48 h, and the expression levels of cyclin D1 and cyclin B1 




Natural products have always been the preferred 
option of all as it plays an immense role in the 
healthcare and various traditional medicine 
systems of the world.  
 
According to an estimate by World Health 
Organization, 80 % of the world’s population 
relies mainly on traditional medicines for their 
primary health care [15]. Coumarins are a class 
of natural compounds widely distributed in plants 
having low toxicity in the humans [16,17]. They 
possess several biological activities such as anti-
bacterial [18], anti-platelet [19] vasodilatatory 
[20], anti-asthmatic [21] and anti-mutagenic [22] 
anti-tumourigenic activity [23-26]. Coumarins and 
their derivative compounds have been used in 
clinical treatment, alone or in combination 
therapy, of various malignant cancers, such as 
renal, lung and kidney carcinoma and malignant 
melanoma [27]. Scopoletin (6-methoxy-7-
hydroxycomarin) is a phenolic coumarin and an 
important member of the group of phytoalexins 
isolated from many plants.  
 
Studies have shown that scopoletin and its 
synthetic derivatives exhibit anticancer activity 
against mammary (MCF-7 and MDA-MB 231) 
and colon (HT-29) carcinoma cells [28]. In this 
study we found that scopoletin reduced the 
expression levels of cyclin D1 in androgen-
dependent manner and caused cell cycle arrest 
at G2/M phase and induced early and late 
apoptosis in human prostate cancer cells 
(LNCaP). As it has been found that the elevated 
levels of cyclin D1 promote prostate cancer 
development by reducing its dependence on 
androgen stimulation [29]. The ability of 
scopoletin to affect cell cycle regulating 
molecules is an important finding making it an 
essential natural product for the development of 





The findings of this study indicate that scopoletin 
exhibits potent anticancer activity by inducing 
apoptosis, cell cycle arrest and down regulating 
the expression of cyclin D1 levels in human 
prostate cancer (LNCaP) cells, thus making it an 
important natural product for the development of 
chemotherapeutic agents against prostate 
cancers and paving a way to elucidate further the 
mechanism of its action in order to make it more 
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